John Sampson to lead Duke’s physician practice of over 1,500 members

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Sampson was elected president of the Private Diagnostic Clinic, the physician practice of Duke Health, with 1,650 members practicing in Duke hospitals and more than 100 clinics in North Carolina.

Sampson will continue to serve as chair of the Duke Department of Neurosurgery. The PDC is one of the first and the largest academic multi-specialty group practices in the U.S., with 1.7 million patient visits in FY18 and $850 million in total revenue.

In addition to patient care, PDC members conduct research and serve as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke’s clinical, research, and academic missions.

In this role, Sampson will provide strategic direction and oversight of the financial and management aspects of the physician organization. This includes implementing initiatives to best position the PDC for continued growth and success, and leading, on behalf of PDC members, the due diligence and negotiations of the potential integration of the PDC and Duke University Health System.

Sampson is the Robert H. and Gloria Wilkins Distinguished Professor and co-leader of the Duke Cancer Institute Neuro-Oncology program. He is a recognized leader in the surgical resection and experimental treatment of complex brain tumors.

He currently focuses his clinical practice on treating patients with benign and malignant brain tumors and divides his time between his clinical practice and an active research laboratory investigating new modalities of direct brain tumor infusion and immunotherapy.

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login